JP2016512493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512493A5 JP2016512493A5 JP2015562425A JP2015562425A JP2016512493A5 JP 2016512493 A5 JP2016512493 A5 JP 2016512493A5 JP 2015562425 A JP2015562425 A JP 2015562425A JP 2015562425 A JP2015562425 A JP 2015562425A JP 2016512493 A5 JP2016512493 A5 JP 2016512493A5
- Authority
- JP
- Japan
- Prior art keywords
- ondansetron
- tablet
- hypromellose
- tablets
- seal coat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 31
- 229960005343 ondansetron Drugs 0.000 claims 28
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 7
- 229960003943 hypromellose Drugs 0.000 claims 7
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000003449 preventive effect Effects 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 229920000831 ionic polymer Polymers 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- -1 sodium citrate anhydride Chemical class 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782395P | 2013-03-14 | 2013-03-14 | |
| US61/782,395 | 2013-03-14 | ||
| PCT/IB2014/001633 WO2014181195A2 (en) | 2013-03-14 | 2014-03-14 | Antiemetic extended release solid dosage forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512493A JP2016512493A (ja) | 2016-04-28 |
| JP2016512493A5 true JP2016512493A5 (https=) | 2017-04-20 |
| JP6282676B2 JP6282676B2 (ja) | 2018-02-21 |
Family
ID=51528070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562425A Active JP6282676B2 (ja) | 2013-03-14 | 2014-03-14 | 制吐作用のある徐放性固形製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20140271851A1 (https=) |
| EP (1) | EP2983664B1 (https=) |
| JP (1) | JP6282676B2 (https=) |
| KR (1) | KR102270521B1 (https=) |
| CN (2) | CN112274489A (https=) |
| AU (1) | AU2014264342B2 (https=) |
| BR (1) | BR112015022398B1 (https=) |
| CA (1) | CA2905553C (https=) |
| CL (1) | CL2015002666A1 (https=) |
| ES (1) | ES2946985T3 (https=) |
| HK (1) | HK1223012A1 (https=) |
| IL (1) | IL241580B (https=) |
| MX (1) | MX378261B (https=) |
| NZ (1) | NZ712159A (https=) |
| PH (1) | PH12015502093B1 (https=) |
| RU (1) | RU2679448C2 (https=) |
| SG (1) | SG11201507450TA (https=) |
| WO (2) | WO2014181195A2 (https=) |
| ZA (1) | ZA201506961B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015022398B1 (pt) | 2013-03-14 | 2022-01-11 | Redhill Biopharma Ltd | Comprimido de ondansetrona e preparação farmacêutica embalada |
| CA2941829C (en) * | 2014-03-11 | 2021-11-02 | Redhill Biopharma Ltd | Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms |
| CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
| KR102300335B1 (ko) * | 2018-10-19 | 2021-09-10 | 주식회사 삼양홀딩스 | 아프레피탄트의 경구용 조성물 |
| KR20250107210A (ko) * | 2022-11-03 | 2025-07-11 | 루모스 파마, 인크. | 이부타모렌의 압축형 경구 제형 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4720353A (en) * | 1987-04-14 | 1988-01-19 | Richardson-Vicks Inc. | Stable pharmaceutical w/o emulsion composition |
| US6090411A (en) * | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
| US6733789B1 (en) * | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
| EP1239840B1 (en) | 1999-12-09 | 2005-04-06 | Alza Corporation | Antiviral medication |
| WO2003024427A1 (en) | 1999-12-20 | 2003-03-27 | Temple University Of The Commonwealth System Of Higher Education | Tableted oral extended release dosage form |
| US6936275B2 (en) | 1999-12-20 | 2005-08-30 | Scolr, Inc. | Amino acid modulated extended release dosage form |
| US20020044962A1 (en) * | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
| US6500457B1 (en) * | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
| US20020172712A1 (en) * | 2001-03-19 | 2002-11-21 | Alan Drizen | Antiemetic, anti-motion sustained release drug delivery system |
| GB0119012D0 (en) * | 2001-08-03 | 2001-09-26 | Strakan Group Plc | Transdermal delivery of drugs |
| GB0129489D0 (en) * | 2001-12-10 | 2002-01-30 | Quadrant Healthcare Uk Ltd | Sustained-release compositions |
| US20050131045A1 (en) * | 2002-04-30 | 2005-06-16 | Judith Aronhime | Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them |
| US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| JP2006516977A (ja) | 2003-01-13 | 2006-07-13 | ダイノゲン ファーマシューティカルズ，インコーポレイテッド | 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法 |
| EP1683526B1 (en) | 2003-11-14 | 2012-04-11 | Senju Pharmaceutical Co., Ltd. | Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac |
| RU2382637C2 (ru) * | 2004-04-30 | 2010-02-27 | Астеллас Фарма Инк. | Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию |
| CN101132777A (zh) * | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
| CA2635313C (en) | 2005-12-29 | 2013-12-31 | Osmotica Corp. | Triple combination release multi-layered tablet |
| US20070190141A1 (en) * | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
| US20080004260A1 (en) * | 2006-06-29 | 2008-01-03 | Transcept Pharmaceuticals, Inc. | Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions |
| JP5661281B2 (ja) * | 2006-08-18 | 2015-01-28 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングＥｖｏｎｉｋ Ｒｏｅｈｍ ＧｍｂＨ | 良好な水溶解性を有する作用物質のための作用物質の制御送達を有する医薬組成物 |
| CN100584319C (zh) | 2006-10-16 | 2010-01-27 | 北京科信必成医药科技发展有限公司 | 群孔释放渗透泵控释片及其制备方法 |
| CA2667207A1 (en) | 2006-10-25 | 2008-05-02 | Mcneil-Ppc, Inc. | Ibuprofen composition |
| GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
| CN101568351B (zh) * | 2006-12-22 | 2012-05-30 | 3M创新有限公司 | 控制释放的组合物和方法 |
| WO2009118763A1 (en) * | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Multilayered pharmaceutical compositions and processes thereof |
| US20100196291A1 (en) * | 2009-01-30 | 2010-08-05 | Laurence Halimi | Personal care sunscreen compositions having reduced eye irritation |
| WO2010100657A2 (en) * | 2009-03-04 | 2010-09-10 | Fdc Limited | A novel oral controlled release dosage forms for water soluble drugs |
| US20110003005A1 (en) * | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| RU2427389C2 (ru) * | 2009-10-09 | 2011-08-27 | Александр Владимирович Диковский | Фармацевтическая композиция для профилактики и лечения инфекционных и неинфекционных диарей |
| CA2782163A1 (en) * | 2009-11-30 | 2011-06-03 | Aptalis Pharmatech, Inc. | Ondansetron orally disintegrating tablet compositions for prevention of nausea and vomiting |
| EP2515882A2 (en) * | 2009-12-22 | 2012-10-31 | Abbot Healthcare Private Limited | Controlled release pharmaceutical composition |
| CN102892405A (zh) | 2009-12-28 | 2013-01-23 | 莫诺索尔克斯有限公司 | 包含昂丹司琼的可经口施用的膜剂型 |
| US8916194B2 (en) | 2010-08-30 | 2014-12-23 | Lupin Limited | Controlled release pharmaceutical compositions of milnacipran |
| US20120128730A1 (en) * | 2010-11-23 | 2012-05-24 | Nipun Davar | Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron |
| BR112015022398B1 (pt) | 2013-03-14 | 2022-01-11 | Redhill Biopharma Ltd | Comprimido de ondansetrona e preparação farmacêutica embalada |
-
2014
- 2014-03-14 BR BR112015022398-2A patent/BR112015022398B1/pt active IP Right Grant
- 2014-03-14 AU AU2014264342A patent/AU2014264342B2/en active Active
- 2014-03-14 RU RU2015143993A patent/RU2679448C2/ru active
- 2014-03-14 CN CN202011222247.XA patent/CN112274489A/zh active Pending
- 2014-03-14 MX MX2015012970A patent/MX378261B/es unknown
- 2014-03-14 CN CN201480024401.9A patent/CN105530935A/zh active Pending
- 2014-03-14 US US14/212,954 patent/US20140271851A1/en not_active Abandoned
- 2014-03-14 CA CA2905553A patent/CA2905553C/en active Active
- 2014-03-14 ES ES14795266T patent/ES2946985T3/es active Active
- 2014-03-14 US US14/212,694 patent/US9636305B2/en active Active
- 2014-03-14 SG SG11201507450TA patent/SG11201507450TA/en unknown
- 2014-03-14 NZ NZ712159A patent/NZ712159A/en not_active IP Right Cessation
- 2014-03-14 EP EP14795266.7A patent/EP2983664B1/en active Active
- 2014-03-14 WO PCT/IB2014/001633 patent/WO2014181195A2/en not_active Ceased
- 2014-03-14 WO PCT/IB2014/001589 patent/WO2014184662A2/en not_active Ceased
- 2014-03-14 HK HK16111017.8A patent/HK1223012A1/zh unknown
- 2014-03-14 JP JP2015562425A patent/JP6282676B2/ja active Active
- 2014-03-14 KR KR1020157028825A patent/KR102270521B1/ko active Active
-
2015
- 2015-09-10 IL IL241580A patent/IL241580B/en active IP Right Grant
- 2015-09-14 PH PH12015502093A patent/PH12015502093B1/en unknown
- 2015-09-14 CL CL2015002666A patent/CL2015002666A1/es unknown
- 2015-09-18 ZA ZA2015/06961A patent/ZA201506961B/en unknown
-
2017
- 2017-03-22 US US15/466,214 patent/US20170189340A1/en not_active Abandoned
- 2017-08-16 US US15/678,386 patent/US20180028452A1/en not_active Abandoned
-
2020
- 2020-07-01 US US16/918,538 patent/US20200330392A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298998B2 (en) | Pharmaceutical formulations of a hif hydroxylase inhibitor | |
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| JP2006505566A5 (https=) | ||
| JP2013511507A5 (https=) | ||
| JP2016512493A5 (https=) | ||
| JP2016504384A5 (https=) | ||
| JP2016523846A5 (https=) | ||
| IL292262B2 (en) | Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid | |
| JP2017537168A5 (https=) | ||
| JP2014533656A5 (https=) | ||
| JP2009517466A5 (https=) | ||
| JP2008519070A5 (https=) | ||
| US20150140084A1 (en) | Acid resistant banding solution for two piece hard capsules | |
| JP2019530706A5 (https=) | ||
| CN102225202A (zh) | 一种包含阿司匹林和质子泵抑制剂的复方制剂 | |
| JP2010538062A5 (https=) | ||
| CN115025060A (zh) | 含ω-3脂肪酸酯和他汀类的口服给药复合制剂 | |
| JP2019218379A5 (https=) | ||
| EP2740471B1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
| JP2015531749A5 (https=) | ||
| JP2018039810A5 (https=) | ||
| RU2015143993A (ru) | Твердые лекарственные формы, обладающие противорвотным действием, с замедленным высвобождением | |
| ES2663357T3 (es) | Formulaciones de mazindol | |
| JP2017214341A (ja) | 経口医薬製剤 | |
| JP2015120758A5 (https=) |